Amalgamation of innovations in cancer treatment
Cancer Cell Biology & Genetics
Cancer is caused when cells within the body accumulate genetic mutations and start to grow in an uncontrolled manner. Understanding how cancer develops and progresses, including how gene mutations drive the growth and spread of cancer cells, and how tumours interact with their surrounding environment, is vital for the discovery of new targeted cancer treatments.
Cancer & Stem Cell Therapy
Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. Stem Cells and Tumours cancer cells also have the characteristic which is also associated with normal stems cells. Stem Cell Therapy is using to prevent the disease. Stems cells transplant is used to treatment of cancer like leukaemia, multiple myeloma & lymphoma. Cord Blood Stem and Cancer cord blood contains haematopoietic (blood) stem cell. They have long been used in stem cell treatments for leukaemia, blood and bone marrow disorders when chemotherapy is used.
Cancer can occur anywhere in the body. The most common sites of cancer among men include lung, prostate, colon, rectum, stomach and liver. And those for among women are breast, colon, rectum, lung, cervix and stomach. Cancers are often described by the body part that they originated in. However, some body parts contain multiple types of tissue, so for greater precision, cancers can additionally be classified by the type of cell that the tumour cells originated from. The type of cancer a person has needed to be known properly as different types of cancer can behave very differently and respond to different treatments.
A cancer biomarker refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker may be a molecule secreted by a tumour or a specific response of the body to the presence of cancer. Genetic, epigenetic, proteomic, glycolic, and imaging biomarkers can be used for cancer diagnosis, prognosis, and epidemiology. While some cancer biomarkers can be used to predict how aggressively your cancer will grow, and are therefore useful for assessing your prognosis, the most promising use of biomarkers today is to identify which therapies a patient’s cancer may or may not respond to.
The traditional use of nanotechnology in cancer therapeutics has been to improve the pharmacokinetics and reduce the systemic toxicities of chemotherapies through the selective targeting and delivery of these anticancer drugs to tumor tissues.
Cancer pharmacology plays a key role in drug development. In both the laboratory and the clinic, cancer pharmacology has had to adapt to the changing face of drug development by establishing experimental models and target orientated approaches. It also focuses on developing experimental approaches to the clinical treatment of cancer through research that bridges the fields of molecular carcinogenesis, biochemical pharmacology, radiation biology, and clinical pharmacology. It generally involves the pharmacological and oncological aspects of drugs at both.
The journal invites different types of articles including original research article, review articles, short note communications, case reports, Editorials, letters to the Editors and expert opinions & commentaries from different regions for publication.
A standard editorial manager system is utilized for manuscript submission, review, editorial processing and tracking which can be securely accessed by the authors, reviewers and editors for monitoring and tracking the article processing. Manuscripts can be uploaded online at Editorial Tracking System (https://www.longdom.org/editorial-tracking/publisher.php) or forwarded to the Editorial Office at https://www.longdom.org/eye-diseases-and-disorders.html
The Journals includes around 150Abstracts and 100 Keynote speakers have given their valuable words. The meet has provided a great scope for interaction of professionals including in addition to clinical experts and top-level pathologists and scientists from around the globe, on a single platform.
Journal of Molecular Oncology Research